http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100321312-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2236-33 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-57 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate | 1999-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2002-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-100321312-B1 |
| titleOfInvention | Use of costunolide as antiinflammatory agent |
| abstract | The present invention is a sesquiterpene lactone compound extracted from the leaves of Magnolia grandiflora L., which can be used as a therapeutic agent for inflammatory diseases and immune diseases, to costunolide having the structure of Formula 1 In particular, these compounds inhibit the production of nitric oxide (NO) or tumor necrosis factor-alpha (TNF-α), which are important factors regulating the body's immune system, and are important transcription factors for expression of inflammatory mediators. By inhibiting the activation of phosphorus NF-κB, it can be used as an effective treatment of inflammation-related diseases and immune diseases caused by overproduction of nitric oxide or tumor necrosis factor-alpha or activation of NF-κB.n n n n n n n n n n Costunolide |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100933738-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-100929098-B1 |
| priorityDate | 1999-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 325.